Literature DB >> 25428759

Angelman syndrome in adulthood.

Anna M Larson1, Julianna E Shinnick, Elias A Shaaya, Elizabeth A Thiele, Ronald L Thibert.   

Abstract

Angelman syndrome (AS) is a neurogenetic disorder. The goal of this study was to investigate the primary health issues affecting adults with AS and to further characterize the natural history and genotype-phenotype correlations. Standardized phone interviews with caregivers for 110 adolescents and adults with AS were conducted. The impact of age, sex, and genotype on specific outcomes in neurology, orthopedics, internal medicine, and psychiatry were investigated. The mean age of individuals with AS was 24 years (range 16-50y). Active seizures were present in 41% of individuals, and 72% had sleep dysfunction. Significant constipation was present in 85%, and 32% were overweight or obese, with obesity disproportionately affecting women. Scoliosis affected 50% with a mean age at diagnosis of 12 years, and 24% of those diagnosed with scoliosis required surgery, an intervention disproportionately affecting men. Sixty-eight percent were able to walk independently, and 13% were able to speak 5 or more words. Self-injurious behavior was exhibited in 52% of individuals. The results of this study indicate that epilepsy severity may assume a bimodal age distribution: seizures are typically most severe in early childhood but may recur in adulthood. While late-adolescent and adult sleep patterns were improved when compared to the degree of sleep dysfunction present during infancy and childhood, the prevalence of poor sleep in adults remained quite high. Primary areas of clinical management identified include the following: seizures, sleep, aspiration risk, GERD, constipation, dental care, vision, obesity, scoliosis, bone density, mobility, communication, behavior, and anxiety.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Angelman syndrome; adults; behavior; seizures; self-injury

Mesh:

Substances:

Year:  2014        PMID: 25428759      PMCID: PMC5534346          DOI: 10.1002/ajmg.a.36864

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  48 in total

1.  Evolution of seizures and electroencephalographical findings in 23 cases of deletion type Angelman syndrome.

Authors:  Naoko Uemura; Akiko Matsumoto; Miho Nakamura; Kazuyoshi Watanabe; Tamiko Negoro; Toshiyuki Kumagai; Kiyokuni Miura; Takashi Ohki; Seiji Mizuno; Akihisa Okumura; Kohzaburo Aso; Fumio Hayakawa; Yoko Kondo
Journal:  Brain Dev       Date:  2005-08       Impact factor: 1.961

Review 2.  Angelman syndrome (AS, MIM 105830).

Authors:  Griet Van Buggenhout; Jean-Pierre Fryns
Journal:  Eur J Hum Genet       Date:  2009-05-20       Impact factor: 4.246

3.  Age related change in social behavior in children with Angelman syndrome.

Authors:  Dawn Adams; Kate Horsler; Chris Oliver
Journal:  Am J Med Genet A       Date:  2011-05-12       Impact factor: 2.802

Review 4.  Behaviour problems in Angelman syndrome.

Authors:  J A Summers; D B Allison; P S Lynch; L Sandler
Journal:  J Intellect Disabil Res       Date:  1995-04

5.  Communication development in Angelman's syndrome.

Authors:  N Jolleff; M M Ryan
Journal:  Arch Dis Child       Date:  1993-07       Impact factor: 3.791

6.  Angelman syndrome in three adult patients with atypical presentation and severe neurological complications.

Authors:  G J Van Buggenhout; M J Descheemaeker; P Thiry; J C Trommelen; B C Hamel; J P Fryns
Journal:  Genet Couns       Date:  2000

7.  Assessment of anticonvulsant effectiveness and safety in patients with Angelman's syndrome using an Internet questionnaire.

Authors:  Daniel H Nolt; J Michael Mott; Wenee L Lopez
Journal:  Am J Health Syst Pharm       Date:  2003-12-15       Impact factor: 2.637

8.  Angelman syndrome: are the estimates too low?

Authors:  R H Buckley; N Dinno; P Weber
Journal:  Am J Med Genet       Date:  1998-12-04

9.  Epilepsy in Angelman syndrome associated with chromosome 15q deletion.

Authors:  A Matsumoto; T Kumagai; K Miura; S Miyazaki; C Hayakawa; T Yamanaka
Journal:  Epilepsia       Date:  1992 Nov-Dec       Impact factor: 5.864

Review 10.  Myoclonic status in nonprogressive encephalopathies: an update.

Authors:  Maurizio Elia
Journal:  Epilepsia       Date:  2009-05       Impact factor: 5.864

View more
  23 in total

Review 1.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

2.  Aberrant aggressive behavior in a mouse model of Angelman syndrome.

Authors:  Lilach Simchi; Hanoch Kaphzan
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

3.  Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.

Authors:  Rebecca Dutta; Jacqueline N Crawley
Journal:  Neuroscience       Date:  2019-11-12       Impact factor: 3.590

4.  Brief Report: Challenging Behaviors in Toddlers and Preschoolers with Angelman, Prader-Willi, and Williams Syndromes.

Authors:  Wei Siong Neo; Bridgette L Tonnsen
Journal:  J Autism Dev Disord       Date:  2019-04

Review 5.  Epilepsy in Angelman syndrome: A scoping review.

Authors:  Debopam Samanta
Journal:  Brain Dev       Date:  2020-09-04       Impact factor: 1.961

Review 6.  Angelman syndrome and melatonin: What can they teach us about sleep regulation.

Authors:  Daniella Buonfiglio; Daniel L Hummer; Ariel Armstrong; John Christopher Ehlen; Jason P DeBruyne
Journal:  J Pineal Res       Date:  2020-10-11       Impact factor: 13.007

7.  Anxiety in Angelman Syndrome.

Authors:  Stacey C Grebe; Danica L Limon; Morgan M McNeel; Andrew Guzick; Sarika U Peters; Wen-Hann Tan; Anjali Sadhwani; Carlos A Bacino; Lynne M Bird; Rodney C Samaco; Leandra N Berry; Wayne K Goodman; Sophie C Schneider; Eric A Storch
Journal:  Am J Intellect Dev Disabil       Date:  2022-01-01

8.  The Cost of Raising Individuals with Fragile X or Chromosome 15 Imprinting Disorders in Australia.

Authors:  Emma K Baker; Sheena Arora; David J Amor; Perrin Date; Meagan Cross; James O'Brien; Chloe Simons; Carolyn Rogers; Stephen Goodall; Jennie Slee; Chris Cahir; David E Godler
Journal:  J Autism Dev Disord       Date:  2021-07-22

Review 9.  Angelman syndrome - insights into a rare neurogenetic disorder.

Authors:  Karin Buiting; Charles Williams; Bernhard Horsthemke
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

10.  Maternal Ube3a Loss Disrupts Sleep Homeostasis But Leaves Circadian Rhythmicity Largely Intact.

Authors:  J Christopher Ehlen; Kelly A Jones; Lennisha Pinckney; Cloe L Gray; Susan Burette; Richard J Weinberg; Jennifer A Evans; Allison J Brager; Mark J Zylka; Ketema N Paul; Benjamin D Philpot; Jason P DeBruyne
Journal:  J Neurosci       Date:  2015-10-07       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.